demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 severe or critically
antiviral and associated therapy
azithromycin COALITION II Covid-19 Brazil ...
chloroquine and derivatives
hydroxychloroquine HYDRA ...
ivermectin Galan Galan
lopinavir/ritonavir REMAP-CAP ... Cao
Lopinavir/ritonavir plus hydroxychloroquine REMAP-CAP ...
remdesivir CAP-China ...

14 studies excluded by filtering options 0

5209 SIMPLE (Grein), 0 2300excludednot a RCTrisk of bias not avaialble
5226 Duke university (Hydroxychloroquine), 2020 210excludedrisk of bias not avaialble
5259 Duke University azithromycin, 2020 210excludedrisk of bias not avaialble
5490 Kurd, 2020 0100selection pending
5599 Karolyi, 2020 0130selection pending
6034 Huang, 2020 0990selection pending
6095 Camprubi, 2020 1110not a RCTrisk of bias not avaialble
6184 Erdem, 2020 2110excludednot a RCTrisk of bias not avaialble
6262 Yamamura, 2020 2300excludednot a RCTrisk of bias not avaialble
6267 Murohashi, 2020 2100excludednot a RCTrisk of bias not avaialble
6287 Kocayigit H, 2020 1100not a RCTrisk of bias not avaialble
6368 Niaee (vs placebo), 2020 213excludedhigh risk of bias
6449 Okumuş, 2020 113high risk of bias
6516 Eslami, 2020 1310not a RCTrisk of bias not avaialble